Research
Print page Print page
Switch language
Hvidovre Hospital - a part of Copenhagen University Hospital
Published

Short-course TLR9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals with HIV infection

Research output: Contribution to journalJournal articlepeer-review

DOI

  1. Reply

    Research output: Contribution to journalLetterpeer-review

  2. Testing Denmark: a Danish Nationwide Surveillance Study of COVID-19

    Research output: Contribution to journalJournal articlepeer-review

  • Line Vibholm
  • Mariane H Schleimann
  • Jesper F Højen
  • Thomas Benfield
  • Rasmus Offersen
  • Katrine Laura Rasmussen
  • Rikke Olesen
  • Anders Dige
  • Jørgen Agnholt
  • Judith Grau
  • Maria Buzon
  • Burghardt Wittig
  • Mathias Lichterfeld
  • Andreas Munk Petersen
  • Xutao Deng
  • Mohammed Abdel-Mohsen
  • Satish K Pillai
  • Sofie Rutsaert
  • Wim Trypsteen
  • Ward De Spiegelaere
  • Linos Vandekerchove
  • Lars Østergaard
  • Thomas A Rasmussen
  • Paul W Denton
  • Martin Tolstrup
  • Ole S Søgaard
View graph of relations

Background: Treatment with latency reversing agents (LRA) enhances HIV-1 transcription in vivo but only leads to modest reductions in the size of the reservoir, possibly due to insufficient immune-mediated elimination of infected cells. We hypothesized that a single drug molecule - a novel toll-like receptor 9 (TLR9) agonist, MGN1703 - could function as an enhancer of innate immunity and an LRA in vivo.

Methods: We conducted a single-arm, open-label study, where 15 virologically suppressed HIV-1 infected individuals on antiretroviral therapy received 60 mg MGN1703 s.c. twice weekly for 4 weeks. We characterized plasmacytoid dendritic cell, NK -and T cell activation using flow cytometry on baseline and after 4 weeks of treatment. HIV-1 transcription was quantified by measuring plasma HIV-1 RNA during MGN1703 administration.

Results: In accordance with the cell-type specific expression of TLR9, MGN1703 treatment led to pronounced activation of plasmacytoid dendritic cells and substantial increases in plasma interferon- 2 levels (p<0.0001). Consistently, transcription of interferon-stimulated genes (e.g. OAS1, ISG15, Mx1; each were p<0.0001) were upregulated in CD4+ T cells as demonstrated by RNA sequencing. Further, proportions of activated cytotoxic NK cells and CD8+ T cells increased significantly during MGN1703 dosing suggesting an enhancement of cellular immune responses. In 6 of 15 participants, plasma HIV-1 RNA increased from <20 copies/mL to >1500 copies/mL (range 21-1571) during treatment.

Conclusions: TLR9 agonist treatment in HIV infection has a dual potential by increasing HIV-1 transcription and enhancing cytotoxic NK cell activation, both of which are key outcomes in HIV-1 eradication therapy. ClinicalTrials.gov: NCT02443935.

Original languageEnglish
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume64
Issue number12
Pages (from-to)1686-1695
ISSN1058-4838
DOIs
Publication statusPublished - 1 Jun 2017

    Research areas

  • Journal Article

ID: 50133083